Physician profile
Howard Johnson, JR.
NPI 1679572747
$798.40
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.51 · 2020: $295 · 2021: $83.86 · 2022: $40.61 · 2023: $127 · 2024: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $282.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $281.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $148.62 | 2019-2021 | |
| Abbvie INC. | $109.88 | 2020-2024 | |
| Novo Nordisk INC | $46.05 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $44.36 | 2020-2021 | |
| Lilly USA, LLC | $40.64 | 2020-2024 | Mounjaro |
| Cequr Corporation | $36.77 | 2023 | Cequr Simplicity |
| Abbott Laboratories | $36.76 | 2024 | Freestyle Libre 3 |
| Boston Scientific Corporation | $30.78 | 2024 | Wavewriter Alpha Prime 16 |
| Merck Sharp & Dohme LLC | $29.61 | 2020 | |
| Eisai INC. | $28.87 | 2020 | |
| Radius Health, INC. | $28.87 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $26.94 | 2020 | |
| Janssen Pharmaceuticals, INC | $26.04 | 2019-2020 | |
| Pfizer INC. | $25.51 | 2022 | |
| Phathom Pharmaceuticals, INC. | $20.14 | 2024 | Voquezna |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $19.32 | 2019 | |
| Akebia Therapeutics INC | $16.73 | 2019 | |
| Daiichi Sankyo INC. | $16.62 | 2023 | Injectafer |
| Xeris Pharmaceuticals, INC. | $16.05 | 2020 | |
| Almatica Pharma LLC | $15.49 | 2024 | Teriparatide, Loreev Xr |
| Arbor Pharmaceuticals, INC. | $11.80 | 2021 | |
| Esperion Therapeutics, INC. | $11.46 | 2021 | |
| Sumitomo Pharma America, INC. | $11.09 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.